Prothrombotic Risk Factors in Children with Acute Lymphoblastic Leukemia Treated with Delayed E. coli Asparaginase (COALL-92 and 97 Protocols)
- 1 January 2000
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 83 (06) , 840-843
Abstract
Hereditary prothrombotic risk factors have been shown to increase the risk of venous thrombosis in children treated with the combination of E. coli asparaginase and steroids. In the present study the role of prothrombotic risk factors in children with ALL treated according to the COALL study protocol was investigated in 108 consecutively recruited childhood patients. The prevalence rates of prothrombotic risk factors [factor V G1691A mutation, the prothrombin G20210A variant, the TT677 methylenetetrahydrofolate reductase genotype, deficiencies of protein C, protein S, antithrombin, elevated lipoprotein (a)] in this cohort were within the range reported for healthy Caucasians, and comparable to previously reported data for other leukemic patients. Venous thromboembolism occurred in 3 of the 108 children (induction n = 1; reinduction n = 2: 2.8%), and none of these children carried a prothrombotic risk factor. The results of the present study, suggest that the role of hereditary and acquired disturbances of coagulation in the development of thromboses might depend on the treatment regimen.Keywords
This publication has 6 references indexed in Scilit:
- Increased Lipoprotein(a) Is an Important Risk Factor for Venous Thromboembolism in ChildhoodCirculation, 1999
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995
- Enhanced thrombin generation, P-von willebrand factor, P-fibrin D-dimer and P-plasminogen activator inhibitor 1: Predictive for venous thrombosis in asparaginase-treated childrenFibrinolysis, 1994
- Increased Thrombin Generation during Fibrinogen and Platelet Recovery as an Explanation for Hypercoagulability in Children with L-Asparaginase Therapy for ALL or NHL: a Preliminary ReportKlinische Padiatrie, 1994
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994
- Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia.Journal of Clinical Oncology, 1987